Ahmedabad (Gujarat) [India], August 6: Intas Pharmaceuticals has launched HETRONIFLY™ (Serplulimab), the first PD-1 inhibitor globally approved for the treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC), in the Indian market. This marks another major milestone, following the
Standard chemotherapy regimens, which are primarily based on testing in relatively young and healthy patients, may be more harmful to older persons with cancer, who frequently battle with other health conditions.
In Phase 3 clinical trial for metastatic pancreatic ductal adenocarcinoma, a four-drug chemotherapy treatment led to a longer overall survival than a two-drug combination.
In the Phase 3 clinical trial for metastatic pancreatic ductal adenocarcinoma, a four-drug chemotherapy treatment led to a longer overall survival than a two-drug combination.
Washington [US], December 2 (ANI): Pancreatic cancer is extremely difficult to treat. By the time it is detected, cancer often has reached an advanced stage, and patients usually do not survive longer than one year after diagnosis. An aggressive chemotherapy regimen is a first-line treatment